A Phase II, Single Arm, Multicenter Study to Assess the Safety, Tolerability and Anti-Tumor Efficacy of DZD9008 With Bevacizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Mutations (WU-KONG29)
Latest Information Update: 27 Feb 2024
At a glance
- Drugs Bevacizumab (Primary) ; Sunvozertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms WU-KONG29
- Sponsors Dizal Pharmaceutical
Most Recent Events
- 27 Feb 2024 New trial record